Financials in USD. Standardized financial statements.
A compact view of how Immunome, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.94M | $9.04M | $14.02M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -23.2% | -35.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.96M | $0 | $0 | $0 | $0 | $755,000 | $615,000 | $521,000 |
| Gross Profit? | $3.99M | $9.04M | $14.02M | $0 | $0 | -$755,000 | -$615,000 | -$521,000 |
| Gross Margin? | +57.4% | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $218.10M | $314.84M | $123.55M | $36.90M | $25.20M | $11.51M | $10.35M | $7.74M |
| Operating Income? | -$214.11M | -$305.80M | -$109.53M | -$36.90M | -$25.20M | -$12.26M | -$10.35M | -$7.74M |
| EBITDA? | -$211.16M | -$151.35M | -$28.00M | -$36.27M | -$24.45M | -$17.04M | -$9.72M | -$7.18M |
| Income Before Tax | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M | -$17.84M | -$10.44M | -$7.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $39,000 |
| Net Income? | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M | -$17.84M | -$10.55M | -$7.84M |
| EPS? | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-1.69 | $-1.84 | $-7.18 |
| Diluted EPS? | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-1.69 | $-1.84 | $-7.18 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality